Foreign Vaccine Manufacturers May Be Asked To Waive Confidentiality
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA may require foreign vaccine producers to waive confidentiality as a condition of licensure, FDA Acting Commissioner Lester Crawford, PhD, said Nov. 18
You may also be interested in...
FDA May Need To Reduce Timeframe For Inspecting Flu Vaccine Facilities, Rep. Davis Says
House Government Reform Committee Chairman Tom Davis (R-Va.) indicated interest in revising FDA's procedures regarding inspection of flu vaccine manufacturing facilities in light of the current supply shortage
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products